Richee Moon

The Interim Budget 2024 emphasized on a healthier future by increasing allocations for Ayushman Bharat initiatives, including the PMAB-Health Infrastructure Mission and the PM Jan Arogya Yojana. However, it remains pertinent to maintain and boost public health funding to meet the National Health Policy 2017 target of 2.5% of GDP by 2025. Consequently, the industry has high expectations from the Union Budget 2024 to further drive growth in this vital sector and support the nation's future well-being. https://lnkd.in/gnn3M-HD

6

3 Comments

#SustainabilityReport #MSNLaboratories #GreenFuture We are delighted to announce the launch of our Sustainability Report 2024! This report highlights the collective efforts driving positive change and contributing to a greener, more sustainable future!!

26

Very insightful read with deep dives and how the sector is shaping up...

4

#Y2KMoment #CDMOindia As the Bio-Secure Act takes centre stage, there is a growing buzz across both affected and beneficiary countries. The big question on everyone's mind in Indian industry: Should we invest now in new technology, infrastructure, R&D, and market reach, or should we wait? Interestingly, this moment reminds me of the Y2K scenario for the Indian IT industry. Back in the late 1990s, the world braced for a potential digital crisis as we approached December 31, 1999. Indian IT firms seized the opportunity, working hard to establish themselves as global leaders. While larger companies initially had the edge, it was the mid and smaller, more agile, and transparent firms that have since become into today's industry giants. So, are there parallels for the Indian CDMO industry today? I believe so..... A ) Y2K had a clear deadline, and so does the Bio-Secure Act. US innovators have a 5-year window to realign and shift supply chains for commercial projects. Of course new molecules will find their homes from day one, which means an immediate inflow of RFPs and due diligence of the service providers. B ) For the Indian CDMO sector, now is the time to act. Building technical capabilities and scaling efficiently should be our focus. Let us not forget—during the Y2K frenzy, poor execution, overpromising, and greed wiped out many IT companies. We must avoid those pitfalls. C ) The IT industry’s success hinged on human capital and brilliant minds. The best HR practices played a crucial role during the Y2K period and beyond. The same applies now to the CDMO industry—talent and leadership will be pivotal in this knowledge based industry as well . This is not just a one-time event; it is a journey. If we handle it right, this could reshape the industry for years to come. We had other countries at that time looking for IT business as our competitors ! And we have the same situation for CDMO today . India prevailed and will do the same this time as well ! The key ! Shift business models, deploy resources with long-term vision, execute responsibly, and deliver consistently. The future is massive !!!

87

12 Comments

🔍 M&A Surge in Indian Pharma Industry: A New Era of Growth and Innovation 🇮🇳💊 The Indian pharmaceutical industry is witnessing a significant wave of mergers and acquisitions (M&A) aimed at driving growth, expanding portfolios, and enhancing market access globally. The strategic partnerships are helping companies streamline operations, increase R&D capabilities, and provide better access to emerging markets. Here’s why this trend is pivotal: 1️⃣ Consolidation for Efficiency: Smaller, innovative companies are joining forces with larger firms to leverage better resources and distribution channels. The synergy is fueling advancements in generics, biologics, and biosimilars. 2️⃣ Global Expansion: Indian pharma companies are exploring international markets through strategic M&As, strengthening their footprint in regulated markets like the US and EU, and building more robust global pipelines. 3️⃣ Innovation Boost: With tech integration at its core, these collaborations are setting the stage for breakthroughs in drug discovery, data analytics, and personalized medicine. 4️⃣ Regulatory Compliance and Cost Advantages: Mergers help streamline processes and manage costs, especially in the face of regulatory hurdles and competitive pricing pressures. Looking ahead, M&A activities are likely to intensify, with companies strategically aligning to harness India's growing role as the "pharmacy of the world." This consolidation and innovation path is set to reinforce India's position in the global healthcare ecosystem. 🌏✨ #Pharmaceuticals #IndiaPharma #MergersAndAcquisitions #Innovation #Healthcare #IndianEconomy

7

We're thrilled to announce Kevin Technologies as our Networking Partner for the 4th Edition of the India Biopharma Leaders Conclave, hosted by BlueTech Media™. Together, we're set to embark on a journey to explore "New Horizons in Biopharma, Biosimilars, & Biologics"! 🚀 . Date: 13th & 14th June, 2024, Hyderabad To Register for the event click https://lnkd.in/d2T9iruW . This year's theme promises a deep dive into the latest advancements shaping the biopharmaceutical landscape, with a spotlight on the exciting realms of biosimilars and biologics. With renowned speakers and eminent leaders from around the globe, this event is set to be a beacon of knowledge and innovation. . Why Attend: 🔍 Gain valuable insights into industry evolution, regulatory changes, and compliance challenges. 🤝 Expand your professional network by connecting with industry peers and potential collaborators. 💡 Discover cutting-edge products, services, and technologies driving biopharma innovation. 🔄 Engage in meaningful discussions to shape the future trajectory of the industry. 🔬 Explore challenges and opportunities, from regulatory hurdles to ethical considerations. . Event Highlights: 🎤 40+ Speakers 🤝 200+ Delegates 🤝 4+ Associations 📰 4+ Media Partners 🤝 15+ Partners . Key Topics Include: 🔬 The future and challenges of biosimilars 🔬 Success rates and challenges in biosimilar R&D 🔬 Quality, safety, and efficacy standards in biosimilars 🔬 Future of cell and gene therapy manufacturing 🔬 Emerging trends in quality assurance for biologics 🔬 Digitalized supply chains in biopharma 🔬 The crucial role of a digital backbone in the industry 🔬 Advances and barriers in CAR-T cell therapies Don't miss this opportunity to be at the forefront of biopharmaceutical innovation! . #Bluetechmedia #IndiaBiopharmaLeadersConclave #pharmaevents #pharmaceutical #Corporate #PharmaEvents #PharmaConferences #PharmaConclave #PharmaLeaders #BlueTechMedia #BiopharmaLeaders #Innovation #Biosimilars #Biologics #IndustryInsights

32

1 Comment

High time to take a leaf from India's book for health care policy making focused on export promotion, import substitution, technology transfer, performance linked incentives, bilateral agreements, strategic ties, human capital development, R&D and scientific collaborations. 💥 Overall, medicines from Indian companies provided $219Bn in savings to the U.S. healthcare system in 2022 and a total of $1.3Tn between 2013 and 2022. 💥47% prescription share of generics in US is filled by Indian Companies lead by Lipid Regulators, Anti Hypertensives, CNS and Mental Health TAs. 💥Indian companies improving market competitiveness in US saving Billions from the national exchequer and providing access to millions of patients. 💥From API and KSM standpoint, Indian policies are centered towards sustainability and profitable growth. 💥 Indian companies do not supply insulins and newer generation diabetes medicines, such as DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 agonists, which are largely still patent protected and represent a growing share of the diabetes market. However, Indian companies supply 43% of traditional diabetes medicines, such as metformin and sulphonylureas, which are less complex small molecules and almost entirely dispensed as generics. https://lnkd.in/d2dsJEza

13

People often view the pharmaceutical industry as indispensable, but imagine a world where it had never existed: Integrated Medicine Flourishing: A well-developed system of integrated medicine would have thrived before the Rockefeller influence, preserving diverse healing traditions. Ayurveda and Naturopathy Leading: In India, Ayurveda and naturopathy would have remained dominant, while homeopathy would have gained widespread popularity. Truth About Disease: The germ and virus theories might never have taken root, allowing a deeper understanding of disease causes and their remedies. No Mass Vaccination: Without mass vaccination campaigns, chronic autoimmune and inflammatory conditions would not have become epidemics. Microbiome Intact: The absence of antibiotics would protect the microbiome—our body's essential health defenders—from destruction. Natural Healing of Acute Diseases: Acute illnesses would be facilitated naturally, aligned with the body's core strength, instead of being suppressed. Minimal Chemical Use: Medicines and chemicals would be used sparingly, reserved only for emergencies. Fewer Surgeries: With the body self-regulating and healing, unnecessary surgeries would be rare. Organ Protection: Acute diseases would eliminate toxins, preventing long-term organ damage. Empowered Populations: People would have the knowledge to maintain health, reconnecting with instincts lost over time. Low Health Costs: Health expenses would be minimal, relying on natural resources like food, exercise, sunlight, water, air, and sleep as medicine. Environmental Mindfulness: Greater awareness of biodiversity, food safety, nutrition, and the importance of self-control, ethics, and spirituality would prevail. Cooperative Communities: A healthy and mentally stable population would foster cooperation over conflict, promoting peace and growth. Respect for Women: A mentally sound society would respect women, reducing crime rates significantly. Sustainable Living: Minimal needs of a healthy population would lead to resource conservation and environmental respect. Awareness of Technology's Impact: The dangers of over-reliance on technology would be recognized and mitigated. Harmony with Nature: Humans and the planet would coexist in balance, free from harm. The pharmaceutical industry has been a tool of deception, often used to suppress, control, and misguide populations. A world without it might have been far more harmonious, sustainable, and self-reliant.

2

Amazed by the kind of #healthcare innovations conceived by these young minds. And most of them are solutions to inspired by real-life situations. The future of healthcare looks bright. Shows how connected the next gen is with the needs and how they're trying to fill the gap with innovative solutions. More power to them!

305

10 Comments

Addressing Healthcare Challenges in India: The Launch of RAPID NEWS Self-Test Kits by Mankind Today, I want to draw attention to some significant health issues that many individuals in India face today. Did You know? In 2023 alone, approximately 300,000 cases of dengue were reported, a disease that can prove fatal if not managed promptly. This alarming statistic underscores the urgent need for accessible testing and timely intervention and dengue fever at times may go undetected. Additionally, around 30% of women in India suffer from urinary tract infections (UTIs). If left untreated, these infections can lead to severe complications, including affecting your kidneys. The importance of early detection and treatment cannot be overstated. Moreover, early menopause is becoming increasingly common, with some women experiencing symptoms as early as 40 years of age. Symptoms such as hot flashes, vaginal dryness, and sleep disturbances can significantly impact quality of life. Unfortunately, these symptoms often go unnoticed or are dismissed, leading to increased anxiety and depression. Proper testing is essential to confirm menopause and provide the necessary support. I am proud to introduce to you RAPID NEWS self-test kits for MENOPUASE, UTI & DENGUE because at Mankind, we believe that everyone deserves access to essential healthcare solutions Benefits of RAPID NEWS Kits: 1. Convenience: Our self-test kits allow individuals to conduct tests in the comfort of their own homes 2. Quick Results: With results available in just minutes, users can make informed decisions about their health without unnecessary delays. 3. Privacy: The kits are designed to ensure user privacy, allowing individuals to test discreetly and confidentially. 4. User-Friendly: Each kit comes with clear instructions, making it easy for anyone to use, regardless of their prior experience with health testing. 5. Empowerment: By providing the tools for self-testing, we empower individuals to take charge of their health, facilitating early detection and timely intervention. Together, let’s take proactive steps towards better health and well-being MANKIND PHARMA LTD

317

19 Comments

MOVIE ON PHARMA BUSINESS INSIGHTS - GET READY FOR DEEP DIVE .

3

1 Comment

Dr. Shridhar Gawade is discussing cutting-edge tools and strategies for detecting DEG and EG impurities. He is delving into practical risk mitigation methods that are transforming the industry at the 2nd Annual Pharma Impurity Conclave 2024. #ebmpic2024 #eminencebusinessmedia #eminencegroupventures

27

It was pleasure to have Podcast on Entrepreneurship with Pratik Pai !! Pls watch the episode and share your thoughts

26

3 Comments